• Explore /
  • Poster
  • / Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

Abstract Poster

Authors

null

Thierry Facon

University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

Thierry Facon , Holger W. Auner , Maria Gavriatopoulou , Sosana Delimpasi , Maryana Simonova , Ivan Spicka , Luděk Pour , Meletios A. Dimopoulos , Iryna Kriachok , Halyna Pylypenko , Xavier Leleu , HANG QUACH , Benjamin Reuben , Tuphan Kanti Dolai , Dinesh Kumar Sinha , Mamta Garg , Don A. Stevens , Jatin J. Shah , Paul G. Richardson , Sebastian Grosicki

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03110562

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8019)

DOI

10.1200/JCO.2021.39.15_suppl.8019

Abstract #

8019

Abstract Disclosures

Similar Posters

First Author: Christopher James Walker

First Author: Xavier Leleu

First Author: Cristina Gasparetto

First Author: Samer Al Hadidi